Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Video Interview: Keryx Reboots Disappointing Product Launch

This article was originally published in Scrip

Executive Summary

Keryx Biopharmaceuticals CEO Greg Madison reveals to Mike Ward, global director of content for Informa's pharma insights portfolio, how the company turned around what was initially a disappointing launch of the company's first product. Auryxia (ferric citrate) was first launched in 2015 for the control of serum phosphorus levels in dialysis patients with chronic kidney disease. However, as Madison notes, the launch got off to a rough start with slow sales and a chorus of naysayers. Madison explains how the company revisited its launch strategy, resulting in an increase in sales. The company is now looking at a potential label extension in the US, based on data from a Phase III pivotal study evaluating Auryxia in pre-dialysis patients with iron deficiency anemia—topline results expected in 2Q 2016—and expects to identify a partner for the European market after being granted a strong label for EU marketing authorization in 2015.

You may also be interested in...



AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments

Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.

Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies

Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.

Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options

Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel